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Abstract
Background: In	 Europe	 cardiovascular	 disease	 (CVD)	 is	 responsible	 for	 3.9	million	
deaths	(45%	of	deaths),	being	ischaemic	heart	disease,	stroke,	hypertension	(leading	
to	heart	failure)	the	major	cause	of	these	CVD	related	deaths.	Periodontitis	is	also	a	
chronic	non‐communicable	disease	(NCD)	with	a	high	prevalence,	being	severe	peri‐
odontitis,	affecting	11.2%	of	the	world's	population,	the	sixth	most	common	human	
disease.
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1  | INTRODUC TION
Non‐communicable	 diseases	 (NCDs)	 are	 rising	 in	 prevalence	 glob‐
ally	in	line	with	an	increasingly	ageing	population,	refined	diets	and	
sedentary	lifestyles	and	account	for	41	million	deaths	each	year,	or	
71%	of	all	global	deaths	(G.	B.	D.	Risk	Factors	Collaborators,	2016).	
Approximately	 80%	 of	 people	 over	 65‐years	 of	 age	 in	 the	 United	
States	are	affected	by	one	or	more	NCDs	and	77%	exhibit	at	least	two	
NCDs,	creating	a	significant	burden	of	disease	to	individuals	and	to	
the	healthcare	economy	(Centres	for	Disease	Control	&	Prevention,	
2011).	The	comorbid	presence	of	two	or	more	NCDs	presents	a	major	
challenge	to	the	economy,	equating	to	two‐thirds	of	all	health	costs	in	
the	United	States	(Centres	for	Disease	Control	&	Prevention,	2013);	
however,	<1%	USA	health	expenditure	is	focussed	on	prevention	to	
improve	overall	health	(U.S.	Senate	Committee	on	Health,	2011).
The	 greatest	 global	 NCD	 burden	 arises	 due	 to	 cardiovascular	
disease	 (CVD),	 responsible	 for	 17.9	million	 deaths	 (a	 third	 of	 total	
mortality),	and	45%	of	NCD‐induced	mortality	(Roth	et	al.,	2017).	In	
Europe,	CVD	 is	 responsible	 for	3.9	million	deaths	 (45%	of	deaths),	
and	whilst	CVD	mortality	rates	are	reducing,	the	absolute	numbers	
have	 increased	 in	 the	 last	 25	 years,	 due	 to	 an	 increasingly	 ageing	
population	 (Wilkins	 et	 al.,	 2017).	 Ischaemic	 heart	 disease,	 stroke,	
hypertension	(leading	to	heart	failure),	rheumatic	heart	disease,	car‐
diomyopathy	and	atrial	 fibrillation	cause	over	95%	of	CVD‐related	
deaths	(Roth	et	al.,	2015).
In	this	consensus	report,	the	term	CVD	is	used	as	a	general	term	
for	 atherosclerotic	 diseases,	 principally	 coronary	 heart	 disease,	
cerebrovascular	disease	and	peripheral	vascular	disease.	A	number	
of	chronic	infectious,	inflammatory	and	immune	diseases	are	associ‐
ated	with	significantly	higher	risks	of	adverse	cardiovascular	events,	
including	 rheumatoid	arthritis,	psoriasis,	 systemic	 lupus	erythema‐
tosus	and	periodontitis	(Roth	et	al.,	2015),	consistent	with	the	the‐
sis	that	chronic	elevations	in	the	systemic	inflammatory	burden	are	
causally	related	to	CVD	development	and	its	sequelae.	Whilst	there	
is	 evidence	 for	 over	 50	 gene	 polymorphisms	 playing	 a	 role	 in	 the	
modulation	of	 atherogenesis	 (Holdt	&	Teupser,	 2015),	 effect	 sizes	
are	small	and	the	major	traditional	risk	factors	for	CVD	remain	the	
lifestyle	factors,	principally	tobacco	smoking,	dyslipidaemia,	hyper‐
tension	and	altered	glucose	metabolism.	The	latter	correlate	strongly	
with	diets	high	in	saturated	fats,	salt	and	refined	sugars	and	contrib‐
ute	to	obesity	and	type	2	diabetes	mellitus,	major	attributable	risk	
factors	for	myocardial	infarction	(Joseph	et	al.,	2017).	The	same	risk	
factors	account	for	over	90%	of	the	stroke	burden	(O'Donnell	et	al.,	
2016),	 yet	 all	 are	modifiable	 through	 improved	 lifestyles	 including	
reducing	 salt,	 saturated	 fat	and	 refined	carbohydrate	 intake,	exer‐
cising,	 increasing	 intake	 of	 antioxidant	micronutrients	 and	 regular	
moderate	alcohol	consumption	(Joseph	et	al.,	2017).
Periodontitis	 is	 also	 a	 NCD	 with	 a	 high	 prevalence	 of	 45%–
50%	 overall,	 with	 the	 most	 severe	 form	 affecting	 11.2%	 of	 the	
world's	population,	being	 the	 sixth	most	 common	human	disease	
(Kassebaum	et	al.,	2014).	The	Global	Burden	of	Diseases,	Injuries,	
and	Risk	Factors	Study	(2017)	of	years	 lost	to	disability	 (YLD)	re‐
ported	that	from	1990	to	2017	oral	diseases	(mainly	periodontitis	
and	caries)	 contributed	 the	most	YLD	 in	age‐standardized	preva‐
lence	rates	from	354	diseases	and	injuries	across	195	countries	(G.	
B.	D.	Disease	Injury	&	Incidence	&	Prevalence	Collaborators,	2018).	
There	 is	 now	a	 significant	body	of	 evidence	 to	 support	 indepen‐
dent	associations	between	severe	periodontitis	and	several	NCDs	
including	diabetes	(Chapple,	Genco,	&	Working	group	2013	of	the	
joint	EFP/AAP	Workshop,	2013),	cardiovascular	disease	(Tonetti	et	
Material and Methods: There	 is	now	a	significant	body	of	evidence	 to	support	 in‐
dependent	associations	between	severe	periodontitis	and	several	NCDs,	in	particu‐
lar	CVD.	 In	2012	a	 joint	workshop	was	held	between	 the	European	Federation	of	
Periodontology	 (EFP)	and	 the	American	Academy	of	Periodontology	 to	 review	 the	
literature	relating	periodontitis	and	systemic	diseases,	including	CVD.	In	the	last	five	
years	important	new	scientific	information	has	emerged	providing	important	emerg‐
ing	evidence	to	support	these	associations
Results and Conclusions: The	present	review	reports	the	proceedings	of	the	work‐
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al.,	 2013),	 chronic	 obstructive	 pulmonary	 disease	 (Linden,	 Lyons,	
&	Scannapieco,	2013)	and	chronic	kidney	disease	 (CKD)	 (Sharma,	
Dietrich,	 Ferro,	Cockwell,	&	Chapple,	2016).	 Indeed,	 severe	peri‐
odontitis	 is	 independently	 and	 significantly	 associated	 with	 all‐
cause	and	cardiovascular	mortality	in	several	different	populations	
(Linden	 et	 al.,	 2012;	 Sharma	 et	 al.,	 2016).	 Proposed	mechanisms	
include	 bacteraemia	 and	 the	 associated	 systemic	 inflammatory	
sequelae,	 including	elevations	 in	C‐reactive	protein	and	oxidative	
stress	(Schenkein	&	Loos,	2013).	In	populations	with	multimorbid‐
ity,	for	example	chronic	kidney	disease	with	comorbid	diabetes	and	
periodontitis,	periodontitis	is	associated	with	significantly	reduced	
survival	from	all‐cause	and	cardiovascular	mortality	(Sharma	et	al.,	
2016).	It	appears	therefore	that	periodontitis	may	be	a	modifiable	
non‐traditional	risk	factor	for	CVD.
In	 2012,	 a	 joint	 workshop	 was	 held	 between	 the	 European	
Federation	of	Periodontology	(EFP)	and	the	American	Academy	of	
Periodontology	to	review	the	literature	relating	periodontitis	and	
systemic	diseases,	including	CVD.	The	consensus	report	was	based	
upon	 four	 technical	papers	 that	 systematically	 reviewed	 the	evi‐
dence	for	epidemiological	associations	between	periodontitis	and	
incident	CVD	 (Dietrich,	 Sharma,	Walter,	Weston,	&	Beck,	 2013),	
mechanisms	of	 biological	 plausibility	 relating	 to	periodontal	 bac‐
teria	and	systemic	inflammation	(Reyes,	Herrera,	Kozarov,	Roldan,	
&	Progulske‐Fox,	2013;	Schenkein	&	Loos,	2013)	and	periodontal	
intervention	 studies	 (D'Aiuto,	 Orlandi,	 &	 Gunsolley,	 2013).	 The	
workshop	concluded	that	there	was	consistent	and	strong	epide‐
miological	 evidence	 that	 periodontitis	 imparts	 increased	 risk	 for	
future	 atherosclerotic	 cardiovascular	 disease.	 It	 also	 concluded	
that	the	impact	of	periodontitis	on	CVD	was	biologically	plausible,	
via	translocated	circulating	oral	microbiota,	which	may	directly	or	
indirectly	induce	systemic	inflammation	that	impacts	upon	the	de‐
velopment	of	atherothrombogenesis,	and	whilst	in	vitro,	pre‐clin‐
ical	and	clinical	studies	supported	the	 interaction	and	associated	
biological	 mechanisms,	 intervention	 trials	 were	 not	 sufficiently	
adequate	to	draw	further	conclusions	at	that	time.
The	present	workshop	was	jointly	organized	by	the	EFP	and	the	
World	 Heart	 Federation	 (WHF)	 to	 include	 global	 experts	 in	 both	
periodontal	 and	 cardiovascular	disciplines	 and	was	held	 in	Madrid	
on	18th	and	19th	February	2019.	Four	 technical	 reviews	updating	
the	 evidence	 base	 from	 the	 2012	 workshop	 were	 prepared	 and	
supplemented	by	additional	studies	discussed	at	the	workshop.	The	
reviews	focussed	on	epidemiological	associations	(Herrera,	Molina,	
Buhlin,	 &	 Klinge,	 2019),	 mechanistic	 links	 (Schenkein,	 Papapanou,	
Genco,	 &	 Sanz,	 2019),	 results	 from	 intervention	 studies	 (Orlandi,	
Graziani,	&	D’Aiuto,	2019)	and	the	potential	risk	and	complications	
of	periodontal	therapy	in	patients	undertaking	antithrombotic	(anti‐
platelet	and	anticoagulant)	therapy.
Whilst	this	consensus	report	focuses	predominantly	on	relevant	
evidence	published	 since	 the	2012	workshop,	 there	 are	biological	
areas	 that	have	subsequently	come	 to	prominence,	where	 the	un‐
derpinning	body	of	evidence	was	not	covered	in	the	2013	consensus	
report,	and	hence,	certain	pre‐2012	manuscripts	are	referenced	to	
ensure	the	context	of	these	recent	studies	is	clear.
Furthermore,	 section	 4.3	 “What is the effect of statin intake on 
clinical periodontal outcomes?”	and	section	5	“Cardiovascular risks and 
complications of periodontal therapeutic interventions”	were	not	dealt	
in	the	previous	workshop,	and	hence,	a	full	appraisal	of	the	scientific	
evidence	was	carried	out	in	this	consensus	meeting.
Finally,	following	the	review	of	the	presented	evidence,	recom‐
mendations	for	both	medical	and	dental	teams,	as	well	as	patients	
and	the	public,	were	elaborated.
2  | EPIDEMIOLOGIC E VIDENCE ON THE 
A SSOCIATION BET WEEN PERIODONTITIS 
AND C VD
2.1 | Do people with periodontitis have a higher 
prevalence of subclinical cardiovascular disease?
There	 is	evidence	 from	epidemiological	 studies	 that	periodontitis	
patients	 exhibit	 significant	 endothelial	 dysfunction,	measured	 by	
flow‐mediated	dilation	(FMD),	arterial	stiffness	(e.g.	pulse	wave	ve‐
locity—PWV)	and	a	significantly	greater	thickness	of	the	carotid	in‐
tima‐media	(cIMT)	and	elevated	arterial	calcification	scores.	There	
is	one	imaging	study	(ATHEROREMO‐IVUS	study)	associating	high	
levels	of	antibodies	against	periodontal	pathogens	and	a	lower	ex‐
tent	of	positive	atheromatous	plaque	 remodelling	 (de	Boer	et	al.,	
2014).
2.2 | Do people with periodontitis have a higher 
prevalence of coronary artery disease and risk of 
myocardial infarction and other coronary events?
There	is	robust	evidence	from	epidemiological	studies	for	a	positive	
association	 between	 periodontitis	 and	 coronary	 heart	 disease.	 A	
systematic	review	(Dietrich	et	al.,	2013),	which	was	updated	in	prep‐
aration	for	this	workshop,	identified	a	total	of	6	case–control	and	co‐
hort	studies	epidemiological	studies,	published	in	the	last	five	years,	
which	demonstrated	an	 increased	 risk	of	 a	 first	 coronary	event	 in	
patients	with	clinically	diagnosed	periodontitis	or	more	severe	peri‐
odontitis	compared	to	patients	without	periodontitis	or	less	severe	
periodontitis.	Relative	risk	estimates	vary	between	studies,	depend‐
ing	on	population	characteristics	and	periodontitis	case	definitions.	
There	are	two	cohort	studies	reporting	an	association	between	peri‐
odontitis	and	higher	cardiovascular	mortality	(due	to	coronary	heart	
disease	and	cerebrovascular	disease).
2.3 | Do people with periodontitis have a higher 
prevalence of cerebrovascular disease and risk of stroke?
There	is	evidence	from	epidemiologic	studies	for	a	positive	associa‐
tion	between	periodontitis	and	cerebrovascular	disease.	A	system‐
atic	review	(Dietrich	et	al.,	2013),	which	was	updated	in	preparation	
for	this	workshop,	identified	a	total	of	three	case–control	and	cohort	
studies,	which	demonstrate	an	increased	risk	of	a	first	cerebrovascu‐
lar	event	in	patients	with	clinically	diagnosed	periodontitis	or	more	
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severe	periodontitis	compared	to	patients	without	periodontitis	or	
less	severe	periodontitis.	Relative	risk	estimates	vary	between	stud‐
ies,	depending	on	population	characteristics	and	periodontitis	case	
definitions.	 Furthermore,	 a	 recent	 analysis	 of	 data	 from	 the	ARIC	
study	 demonstrated	 an	 association	 between	 periodontal	 profile	
class	 and	 incident	 ischaemic	 stroke.	 In	 this	 cohort,	 patients	 with	
periodontitis	 had	more	 than	 double	 the	 risk	 of	 cardioembolic	 and	
thrombotic	stroke	compared	with	periodontally	healthy	individuals	
(Sen	et	al.,	2018).	 In	addition,	as	previously	documented,	there	are	
two	cohort	studies	reporting	an	association	between	periodontitis	
and	higher	cardiovascular	mortality	(due	to	coronary	heart	disease	
and	cerebrovascular	disease)	(Dietrich	et	al.,	2013).
2.4 | Do people with periodontitis have a higher 
prevalence and incidence of Peripheral Artery 
Disease (PAD)?
There	 is	 limited	 but	 consistent	 evidence	 that	 individuals	 with	
periodontitis	have	a	higher	prevalence	and	incidence	of	PAD	com‐
pared	 to	 individuals	without	periodontitis	 (Yang	et	al.,	2018).	For	
cross‐sectional	 data,	 the	 most	 significant	 evidence	 comes	 from	
two	large,	population‐based	studies	in	the	United	States	(NHANES	
1999–2002)	and	South	Korea	(KoGES‐CAVAS).	Both	studies	found	
a	 positive	 association	 between	 the	 extent	 of	 clinical	 attachment	
loss	(NHANES	1999‐2002)	and	severity	of	radiographic	bone	loss	
(KoGES‐CAVAS)	with	PAD,	defined	using	the	Ankle	Brachial	Index	
(ABI),	with	adjusted	odds	ratios	(OR)	of	2.2	(95%	confidence	inter‐
val	 [1.2;	2.4])	 and	2.0	 (95%	CI	 [1.1;	3.9]),	 respectively	 (Ahn	et	 al.,	
2016;	 Lu,	 Parker,	 &	 Eaton,	 2008).	One	 prospective	 cohort	 study	
conducted	 in	male	veterans	 in	the	United	States	reported	a	posi‐
tive	 association	 between	 periodontitis	 (measured	 by	 severity	 of	
radiographic	 bone	 loss)	 and	 the	 incidence	 of	 PAD	 over	 a	 25‐	 to	
30‐year	follow‐up	period,	with	an	adjusted	OR	of	2.3	(95%	CI	[1.3;	
3.9])	(Mendez	et	al.,	1998).	There	are	no	studies	that	have	evaluated	
the	association	between	periodontitis	and	the	incidence	of	Major	
Adverse	Limb	Events	(MALE).
2.5 | Do people with periodontitis have a higher risk of 
other CVDs or conditions (heart failure, atrial fibrillation)?
Several	 studies	 report	 positive	 associations	 between	 periodontitis	
and	heart	failure.	There	is	evidence	from	a	large	Asian	study	using	the	
Taiwanese	National	Health	Insurance	Research	Database	reporting	a	sig‐
nificantly	higher	incidence	of	atrial	fibrillation	in	individuals	with	periodon‐
tal	diseases	compared	to	individuals	without	periodontal	diseases	(hazard	
ratio—HR	=	1.31,	95%	CI	[1.25,	1.36])	(Chen,	Lin,	Chen,	&	Chen,	2016).
2.6 | Do people with a history of cardiovascular 
disease have a different incidence or progression of 
periodontitis?
There	is	currently	limited	scientific	evidence	that	CVD	is	a	risk	factor	
for	the	onset	or	progression	of	periodontitis.
2.7 | Do people with periodontitis with history of 
cardiovascular disease have a higher chance of 
experiencing a subsequent event?
From	 three	 studies	 investigating	 the	 association	 between	 peri‐
odontitis	and	secondary	cardiovascular	events,	two	large	studies	
did	not	find	a	significant	association	(Dorn	et	al.,	2010;	Reichert	
et	al.,	2016);	however,	a	small	study	(100	subjects)	reported	a	sig‐
nificant	 association	 (HR	=	2.8,	95%	CI	 [1.2;	6.5])	with	 recurrent	
cerebrovascular	events	(Sen	et	al.,	2013).
3  | MECHANISMS THAT MAY E XPL AIN 
THE EPIDEMIOLOGIC AL A SSOCIATIONS 
BET WEEN PERIODONTITIS AND C VD
3.1 | Is there evidence of a higher incidence of 
bacteremia following oral function/intervention in 
periodontitis patients compared to periodontally 
healthy subjects?
There	is	evidence	that	oral	bacterial	species	can	enter	the	circula‐
tion	and	cause	bacteremia,	which	has	been	demonstrated	follow‐
ing	daily	life	activities	(toothbrushing,	flossing,	chewing	or	biting	
an	apple),	although	it	has	been	studied	more	frequently	following	
professional	interventions	(tooth	polishing,	scaling,	tooth	extrac‐
tion,	surgical	extraction	of	third	molars	and	periodontal	probing).
The	risk	of	bacteremia	has	been	associated	with	periodontal	
health	 status	 in	a	 systematic	 review,	 suggesting	a	higher	 risk	of	
bacteremia	 associated	 with	 gingival	 inflammation	 (Tomas,	 Diz,	
Tobias,	Scully,	&	Donos,	2012).	A	recent	randomized	clinical	trial	
(RCT)	 concluded	 that	 periodontal	 therapy	 (by	 means	 of	 scaling	
and	root	planing,	SRP)	 induced	bacteremia	in	both	gingivitis	and	
periodontitis	 patients,	 but	 the	 magnitude	 and	 frequency	 were	
greater	among	periodontitis	patients	(Balejo	et	al.,	2017).
Whilst	 there	 are	methodological	 limitations	 in	 some	of	 the	 re‐
ported	 studies,	 the	 overall	 picture	 supports	 the	 contention	 that	
bacteremia	 results	 from	daily	 life	 activities	 and	oral	 interventions,	
and	it	is	more	frequent	of	longer	duration	and	involves	more	virulent	
bacteria	in	periodontitis	patients.
3.2 | Is there evidence for the presence of oral 
bacteria in atheroma lesions?
There	 is	 evidence	 through	 traces	 of	 DNA,	 RNA	 or	 antigens	 derived	
from	 oral	 bacterial	 species,	mainly	 periodontal	 pathogens,	 that	 have	
been	 identified	 in	 atherothrombotic	 tissues.	 Studies	 have	 attempted	
to	 correlate	 the	 presence	 of	 these	 bacteria	 in	 atherothrombotic	 tis‐
sues,	with	other	sample	sources	(subgingival	plaque,	serum,	etc.),	in	the	
same	patients,	and	these	suggest	that	in	periodontitis	patients	there	is	
a	higher	probability	of	a	positive	correlation	 (Armingohar,	 Jørgensen,	
Kristoffersen,	 Abesha‐Belay,	 &	 Olsen,	 2014;	 Mahendra,	 Mahendra,	
Felix,	&	Romanos,	2013).	At	least	two	studies	have	demonstrated	viable	
P. gingivalis and A. actinomycetemcomitans	 in	 atherothrombotic	 tissue	
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when	culturing	the	atheroma	samples	(Kozarov,	Dorn,	Shelburne,	Dunn,	
&	Progulske‐Fox,	2005;	Rafferty	et	al.,	2011).
3.3 | Do we have evidence that periodontal 
bacteria and/or bacterial products and virulence 
factors influence the pathophysiology of 
atherosclerosis?
Different	animal	models	have	been	employed	 to	provide	evidence	
that	periodontal	pathogens	can	promote	atheroma	formation.	P. gin‐
givalis	has	been	shown	to	accelerate	atherosclerosis	in	murine	mod‐
els,	to	induce	fatty	streaks	in	the	aorta	of	rabbits	and	to	induce	aortic	
and	 coronary	 lesions	 after	 bacteremia	 in	 normocholesterolaemic	
pigs	(Schenkein	&	Loos,	2013).
Recently,	 further	 evidence	 has	 emerged	 using	 hyperlipidemic	
ApoEnull	mice	after	infection	with	P. gingivalis	and	also	with	a	poly‐
microbial	 experimental	 infection	 (P. gingivalis, Treponema denticola, 
Tannerella forsythia and Fusobacterium nucleatum).	 A	 polymicrobial	
infection	 was	 shown	 to	 induce	 aortic	 toll‐like	 receptor	 (TLR)	 and	
inflammasome	 signalling,	 with	 an	 enhanced	 oxidative	 stress	 reac‐
tion	generated	within	the	aortic	endothelial	cells	(Chukkapalli	et	al.,	
2015;	Velsko	et	al.,	2014,	2015).
There	is	also	in vitro	evidence	of	intracellular	entry	by	periodon‐
tal	pathogens	(P. gingivalis, A. actinomycetemcomitans,	etc.)	(Reyes	et	
al.,	2013).	In vivo and in vitro	studies	demonstrate	the	importance	of	
the	fimbriae	of	P. gingivalis	to	host	cell	entry	and	to	promote	athero‐
thrombotic	lesions	in	experimental	models	(Yang	et	al.,	2014).	In vitro 
experiments	 have	 shown	 that	 certain	 bacterial	 strains	 expressing	
P. gingivalis	hemagglutinin	A	(HagA)	have	an	increased	capability	to	
adhere	and	enter	human	coronary	artery	endothelial	cells	(HCAEC)	
(Belanger,	Kozarov,	Song,	Whitlock,	&	Progulske‐Fox,	2012).
3.4 | Do we have evidence that periodontitis 
patients exhibit increased production and/or levels of 
inflammatory mediators that also associated with the 
pathophysiology of atherosclerosis?
There	is	evidence	of	significantly	higher	levels	of	C‐reactive	pro‐
tein	(CRP)	in	periodontitis	patients	versus	healthy	controls	and	in	
CVD	and	periodontitis	 patients	 compared	with	 either	 condition	
alone.	The	effect	of	periodontal	 therapy	has	been	shown	to	as‐
sociate	with	a	significant	decrease	 in	CRP	 levels,	along	with	 im‐
provements	in	surrogate	measurements	of	cardiovascular	health	
(Demmer	et	al.,	2013;	Koppolu	et	al.,	2013;	Patil	&	Desai,	2013).
There	is	evidence	of	elevated	levels	of	serum	interleukin	(IL)‐6	
in	 periodontitis	 patients	 and	 lower	 levels	 of	 IL‐4	 and	 IL‐18.	 The	
effect	 of	 periodontal	 therapy	has	 shown	a	 significant	 decrease	 in	
the	serum	levels	of	IL‐6,	serum	amyloid	A	and	alpha	1	anti‐chymo‐
trypsin.	Peripheral	 neutrophils	 from	periodontitis	 patients	 release	
excess	 IL‐1β,	 IL‐8,	 IL‐6	 and	 tumour	 necrosis	 factor	 (TNF)‐α	 when	
stimulated	by	periodontal	pathogens.	Periodontal	therapy	only	par‐
tially	reduces	the	cytokine	hyper‐reactivity	with	some	evidence	of	a	
constitutively	elevated	response	(Ling,	Chapple,	&	Matthews,	2016).
3.5 | Do we have evidence that periodontitis 
patients develop elevations in thrombotic factors 
that are also associated with the pathophysiology of 
atherothrombosis?
There	 is	 evidence	 of	 significantly	 higher	 levels	 of	 fibrinogen	 in	 peri‐
odontitis	patients	versus	healthy	controls,	and	in	CVD	and	periodonti‐
tis	patients	compared	with	either	condition	alone	(Chandy	et	al.,	2017).	
Periodontal	therapy	appears	to	result	in	a	significant	decrease	in	fibrino‐
gen	levels	(Lopez	et	al.,	2012;	Vidal,	Cordovil,	Figueredo,	&	Fischer,	2013).
There	 is	evidence	 from	different	studies	of	significantly	higher	
levels	 of	 platelet	 activation	 markers	 in	 periodontitis	 patients	 and	
that	 these	 higher	 levels	 may	 be	 reversed	 by	 periodontal	 ther‐
apy	 (Arvanitidis,	Bizzarro,	Alvarez	Rodriguez,	 Loos,	&	Nicu,	2017).	
However,	there	is	conflicting	evidence	that	significantly	higher	levels	
of	plasminogen	activator	inhibitor	(PAI)	are	found	in	periodontitis	pa‐
tients	(Schenkein	&	Loos.,	2003).
3.6 | Do we have evidence that periodontitis 
patients demonstrate elevated serum antibody levels 
that cross‐react with antigens in cardiovascular 
tissues?
There	 is	 evidence	 that	 HSPs	 from	 periodontal	 pathogens	
(Porphyromonas gingivalis,	Tannerella forsythia, Aggregatibacter actin‐
omycetemcomitans and Fusobacterium nucleatum)	generate	antibod‐
ies	 that	 can	 cross‐react	with	 human	HSPs.	 These	 antibodies	 have	
been	shown	to	activate	cytokine	production,	as	well	as	monocyte	
and	endothelial	cell	activation.
The	presence	of	anti‐cardiolipin	antibodies	has	been	significantly	as‐
sociated	with	periodontitis	patients,	which	reversed	following	periodon‐
tal	therapy.	There	is	some	evidence	that	periodontal	pathogens	can	elicit	
antibodies	that	cross‐react	with	cardiolipin	(Schenkein	&	Loos.,	2003).
In	 three	 out	 of	 four	 population‐based	 studies	 (Parogene	 study,	
NHANES	III,	DANHES),	higher	 levels	of	serum	immunoglobulin	 (Ig)G	
against	P. gingivalis	were	associated	with	periodontitis	patients	and	car‐
diovascular	disease	(acute	coronary	syndrome,	death	from	cardiovas‐
cular	 disease	 and	 cardiovascular	 disease).	 The	ATHEROREMO‐IVUS	
study	 failed	 to	demonstrate	an	association	between	serum	 levels	of	
IgG	and	IgA	against	P. gingivalis,	A. actinomycetemcomitans,	T. forsythia 
and P. intermedia	and	major	adverse	cardiac	events	(MACE)	(de	Boer	et	
al.,	2014).	This	is	consistent	with	data	from	Boillot	et	al.	(2016).
3.7 | Do we have evidence that periodontitis 
patients exhibit dyslipidaemia?
There	is	evidence	from	systematic	reviews	that	serum	total	choles‐
terol	 levels,	 low‐density	 lipoproteins	 (LDL),	 triglycerides,	very‐low‐
density	lipoproteins	(VLDL),	oxidized	LDL	and	phospholipase	A2	are	
elevated	 in	periodontitis.	High‐density	 lipoprotein	 (HDL)	 levels	are	
reduced	in	periodontitis	patients	compared	with	controls	(Schenkein	
&	Loos.,	2003).	These	levels	are	reversed	after	periodontal	therapy	
(Teeuw	et	al.,	2014).
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3.8 | Do we have evidence for peripheral blood 
neutrophil hyper‐responsiveness in reactive oxygen 
species and protease production in periodontitis 
patients?
There	 is	strong	mechanistic	evidence	that	peripheral	blood	neutro‐
phils	(PBNs)	from	periodontitis	patients	produce	higher	levels	of	total	
and	extracellular	reactive	oxygen	species	(ROS)	than	healthy	controls,	
under	various	conditions	of	priming	and	stimulation	and	from	unstim‐
ulated	cells	(Ling	et	al.,	2016;	Matthews,	Wright,	Roberts,	Cooper,	&	
Chapple,	 2007a).	 This	 hyper‐reactivity	 to	 stimulation	 by	 periodon‐
tal	 bacteria	 is	 reduced	 following	 successful	 periodontal	 therapy	 to	
control	 patient	 levels,	 but	 the	 unstimulated	 hyperactivity	 remains,	
suggesting	that	constitutive	and	reactive	mechanisms	underlie	neu‐
trophil	 hyper‐responsiveness	 in	 periodontitis	 (Matthews,	 Wright,	
Roberts,	 Ling‐Mountford,	 et	 al.,	 2007b).	 Gene	 expression	 data	 in	
PBNs	support	the	functional	data	(Wright,	Matthews,	Chapple,	Ling‐
Mountford,	&	Cooper,	2008).	Serum	antioxidant	levels	and	those	in	
gingival	 crevicular	 fluid	 (GCF)	are	 reduced	 in	periodontitis	patients,	
reflecting	 increased	ROS	activity	 (Chapple,	Brock,	Milward,	 Ling,	&	
Matthews,	2007).	These	data	are	supported	by	a	study	of	endarter‐
ectomy	samples,	which	demonstrated	evidence	for	activation	of	the	
ROS‐generating	systems	in	neutrophils,	specifically	the	presence	of	
myeloperoxidase	 (MPO),	 cell‐free	 DNA	 and	 DNA‐MPO	 complexes	
(Range	et	al.,	2014).
3.9 | Are there common genetic risk factors 
between periodontitis and CVDs?
There	 is	 scientific	 evidence	 of	 pleiotropy	 between	 periodontitis	
and	cardiovascular	diseases	(Aarabi	et	al.,	2017;	Munz	et	al.,	2018;	
Schaefer	 et	 al.,	 2015,	 2011).	 The	 highly	 pleiotropic	 genetic	 locus	
CDKN2B‐AS1	 (chromosome	 9,	 p21.3)	 associated	with	 coronary	 ar‐
tery	disease,	type	2	diabetes,	ischaemic	stroke	and	Alzheimer’s	dis‐
ease	is	also	consistently	associated	with	periodontitis	(Aarabi	et	al.,	
2017;	 Ernst	 et	 al.,	 2010;	 Loos,	 Papantonopoulos,	 Jepsen,	&	 Laine,	
2015;	Munz	et	al.,	2018).	 Its	function	appears	to	be	related	to	the	
regulation	of	gene	expression	(Hubberten	et	al.,	2019).	Interestingly,	
a	 pilot	 study	 identified	 that	 a	 genetic	 variant	 in	 the	CDKN2B‐AS1 
locus	was	associated	with	the	extent	of	elevated	levels	of	C‐reactive	
protein	in	periodontitis	(Teeuw,	Laine,	Bizzarro,	&	Loos,	2015).
A	 conserved	 non‐coding	 element	within	CAMTA1	 upstream	of	
VAMP3,	also	first	identified	as	a	genetic	susceptibility	locus	for	cor‐
onary	artery	disease,	was	found	to	be	associated	with	periodontitis	
(Schaefer	 et	 al.,	 2015).	 A	GWAS	 suggested	 that	 the	VAMP3	 locus	
was	associated	with	a	higher	probability	of	subgingival	overgrowth	
of	periodontal	pathogens	(Divaris	et	al.,	2012).
There	is	evidence	for	plasminogen	(PLG)	as	a	shared	genetic	risk	
factor	for	coronary	artery	disease	and	periodontitis	(Schaefer	et	al.,	
2015).
The	4th	pleiotropic	locus	between	coronary	artery	disease	and	
periodontitis	is	a	haplotype	block	at	the	VAMP8	 locus	(Munz	et	al.,	
2018).
These	shared	genetic	 factors	suggest	a	mechanistic	 link	or	 im‐
munological	 commonalities	 between	 coronary	 artery	 disease	 and	
periodontitis.	The	impairment	of	the	regulatory	pathways	by	genetic	
factors	may	be	a	common	pathogenic	denominator	of	at	least	coro‐
nary	artery	disease	and	periodontitis.	There	are	indications	that	ab‐
errant	inflammatory	reactivity,	determined	by	genetic	variants	in	the	
loci CDKN2B‐AS1 (ANRIL), PLG, CAMTA1/VAMP3 and VAMP8 could 
partially	explain	the	epidemiological	link	between	periodontitis	and	
cardiovascular	diseases.
4  | E VIDENCE FROM INTERVENTION 
STUDIES
4.1 | Is there an effect of periodontitis treatment in 
preventing or delaying ACVD events?
4.1.1 | Primary prevention
There	 have	 been	 no	 prospective	 randomized	 controlled	
periodontal	 intervention	 studies	 on	 primary	 prevention	 of	
cardiovascular	diseases	(including	first	ischaemic	events	or	car‐
diovascular	 death)	 since	 the	 last	 consensus	 report	 (Tonetti	 et	
al.,	2013).	The	Group	questioned	 the	 feasibility	of	performing	
adequately	 powered	 RCTs	 in	 primary	 prevention	 at	 a	 popula‐
tion	 level	due	 to	 important	ethical,	methodological	 and	 finan‐
cial	considerations.
However,	consistent	observational	evidence	suggests	that	sev‐
eral	oral	health	interventions	including	self‐performed	oral	hygiene	
habits	 (toothbrushing)	 (two	 studies	 (de	 Oliveira,	 Watt,	 &	 Hamer,	
2010;	Park	et	al.,	2019)),	dental	prophylaxis	(one	study	Lee,	Hu,	Chou,	
&	Chu,	2015),	 increased	self‐reported	dental	visits	(one	study	(Sen	
et	 al.,	 2018))	 and	 periodontal	 treatment	 (three	 studies	 (Holmlund,	
Lampa,	&	Lind,	2017;	Lee	et	al.,	2015;	Park	et	al.,	2019))	produced	a	
reduction	in	the	incidence	of	ACVD	events.
Cross‐sectional	data	of	The	Scottish	Health	Surveys	from	1995	
to	2003	pertaining	11,869	men	and	women	(mean	age	of	50	years)	
were	 linked	 to	 a	 database	 of	 hospital	 admissions	 and	deaths	with	
follow‐up	 until	 December	 2007	 (Information	 Services	 Division,	
Edinburgh)	(de	Oliveira	et	al.,	2010).	Participants	who	brushed	less	
than	 once	 a	 day	 exhibited	 the	 highest	 incidence	 of	 ACVD	 events	
(HR	=	1.7,	95%	CI	[1.3;	2.3])	compared	with	those	who	brushed	twice	
a	day,	 indicating	that	self‐performed	oral	hygiene	routines	may	re‐
duce	the	incidence	of	ACVD.
A	retrospective	nationwide,	population‐based	study	in	Taiwan,	in‐
cluding	511,630	participants	with	periodontitis	and	208,713	controls,	
used	the	Longitudinal	Health	 Insurance	Database	2000	to	estimate	
the	 incidence	 rate	of	ACVD	events	 from	2000	 to	2015	 (Lee	 et	 al.,	
2015).	The	hazard	ratio	for	acute	myocardial	infarction	was	reduced	
more	in	the	group	of	periodontitis	patients	who	received	dental	pro‐
phylaxis	 (HR	 =	 0.90,	 95%	CI	 [0.86;	 0.95])	 than	 intensive	 treatment	
(including	 gingival	 curettage,	 scaling	 and	 root	 planing,	 and/or	 peri‐
odontal	 flap	operation	and/or	 tooth	extraction)	 (HR	=	1.09,	95%	CI	
[1.03;	1.15]).	Consistent	reductions	in	the	incidence	rate	of	ischaemic	
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stroke	were	observed	in	both	the	dental	prophylaxis	(HR	=	0.78,	95%	
CI	 [0.75;	0.91])	 and	 intensive	 treatment	 groups	 (HR	=	0.95,	95%	CI	
[0.91;	0.99]).
A	 cohort	 of	 8,999	 patients	 with	 periodontitis	 who	 received	 a	
complete	 (non‐surgical	 and	 if	 needed	 surgical)	 periodontal	 treat‐
ment	protocol	was	followed	between	1979	and	2012	(Holmlund	et	
al.,	2017).	During	the	study	follow‐up,	poor	responders	to	the	peri‐
odontal	treatment	had	an	increased	incidence	of	ACVD	events	(in‐
cidence	 rate	–IR	=	1.28,	95%	CI	 [1.07;	1.53])	 compared	with	good	
responders,	suggesting	that	successful	periodontal	treatment	could	
reduce	the	incidence	of	ACVD	events.
In	the	Atherosclerosis	Risk	 in	Communities	 (ARIC)	study	 includ‐
ing	6,736	participants	followed	during	15	years,	self‐reported	regular	
dental	care	users	had	a	 lower	 risk	 for	 ischaemic	stroke	 (HR	=	0.77,	
95%	CI	 [0.63;	0.94])	 compared	with	episodic	 care	users	 (Sen	et	 al.,	
2018).
In	 a	 prospective	 population‐based	 study	 using	 data	 from	 the	
National	Health	Insurance	System‐National	Health	Screening	Cohort	
(NHISHEALS)	including	247,696	participants	free	from	any	CVD	his‐
tory	recruited	between	2002	and	2003,	reported	that	an	increased	
number	of	dental	caries	lesions,	the	presence	of	periodontitis	and	a	
greater	loss	of	teeth	were	all	associated	with	an	increased	risk	of	fu‐
ture	major	cardiovascular	events	(MACEs),	including	cardiovascular	
death,	acute	myocardial	infarction,	heart	failure,	and	stroke	(Park	et	
al.,	2019).	One	additional	toothbrushing	episode	per	day	was	asso‐
ciated	with	a	reduced	incidence	of	ACVD	events	(HR	=	0.91,	95%	CI	
[0.89,	0.93])	and	regular	professional	cleaning	reduced	the	risk	even	
further	(HR	=	0.86,	95%	CI	[0.82;	0.90]).
In	summary,	progression	of	ACVD	may	be	influenced	by	success‐
ful	periodontal	treatment	independent	of	traditional	CVD	risk	factor	
management.
4.1.2 | Secondary prevention
There	is	only	one	pilot	multicentre	study	on	secondary	prevention	of	
ACVD	events	(PAVE	(Couper	et	al.,	2008;	Offenbacher	et	al.,	2009)),	
which	reported	no	statistically	significant	difference	 in	 the	rate	of	
CVD	 events	 between	 patients	who	 underwent	 treatment	 of	 peri‐
odontitis	versus	community	care	(risk	ratio	–RR	=	0.72,	95%	CI	[0.23;	
2.22]).	Several	methodological	limitations	highlighted	in	the	trial	limit	
the	applicability/usefulness	of	such	evidence	to	inform	the	research	
and	healthcare	communities.
Thus,	there	is	insufficient	evidence	to	support	or	refute	the	po‐
tential	benefit	of	the	treatment	of	periodontitis	in	preventing	or	de‐
laying	ACVD	events	(Li	et	al.,	2017).
4.2 | What is the effect of the treatment of 
periodontitis in improving surrogate parameters of 
CVD?
Table	 1	 summarizes	 the	 evidence	 on	 the	 effect	 of	 periodontal	
therapy	 on	 surrogate	 markers	 of	 CVD.	 There	 is	 moderate	 evi‐
dence	 for	 reduction	 of	 low‐grade	 inflammation	 as	 assessed	 by	
serum	 levels	of	CRP,	 IL‐6	and	 improvements	 in	surrogate	meas‐
ures	of	endothelial	function	(flow‐mediated	dilatation	of	the	bra‐
chial	artery).
Moderate	 evidence	 suggests	 that	 periodontal	 treatment	 does	
not	have	an	effect	on	lipid	fractions	whilst	there	is	limited	evidence,	
suggesting	that	periodontal	treatment	reduces	arterial	blood	pres‐
sure	and	stiffness,	 subclinical	ACVD	 (as	assessed	by	mean	carotid	
intima‐media	 thickness)	 and	 insufficient	 evidence	 of	 an	 effect	 on	
ACVD	biomarkers	of	coagulation,	endothelial	cell	activation	and	ox‐
idative	stress.
4.3 | What is the effect of statin intake on clinical 
periodontal outcomes?
Statins	 are	 medications	 prescribed	 to	 decrease	 LDL	 cholesterol.	
Numerous	trials	have	demonstrated	their	benefit	for	the	prevention	
of	cardiovascular	diseases	(Yebyo,	Aschmann,	Kaufmann,	&	Puhan,	
2019).
Interestingly,	statins	possess	various	additional	properties	rele‐
vant	to	the	pathogenesis	and	treatment	of	periodontitis	(Estanislau	
et	al.,	2015).	In	particular,	it	has	been	reported	that	statins	are	anti‐
inflammatory	(Koh	et	al.,	2002;	Paumelle	et	al.,	2006;	Quist‐Paulsen,	
2010;	Rosenson,	Tangney,	&	Casey,	1999;	Sakoda	et	al.,	2006)	can	
promote	bone	formation	(Garrett,	Gutierrez,	&	Mundy,	2001;	Liu	et	
al.,	2012;	Mundy	et	al.,	1999;	Viereck	et	al.,	2005),	can	inhibit	matrix	
metalloproteinases	(MMPs)	(Koh	et	al.,	2002;	Luan,	Chase,	&	Newby,	
2003;	 Poston	 et	 al.,	 2016)	 and	 possess	 anti‐microbial	 properties	
(Ting,	Whitaker,	&	Albandar,	2016).
A	 systematic	 review	 with	 meta‐analysis	 of	 pre‐clinical	 in	 vivo	
trials	reported	a	positive	effect	of	local	or	systemic	statin	adminis‐
tration	for	the	prevention	of	alveolar	bone	loss	in	experimental	peri‐
odontitis	models	in	rodents	(Bertl	et	al.,	2018).
Several	observational	clinical	studies	have	evaluated	the	effect	of	
systemic	statin	intake	on	periodontal	conditions	(Lindy,	Suomalainen,	
Mäkelä,	&	Lindy,	2008;	Meisel,	Kroemer,	Nauck,	Holtfreter,	&	Kocher,	
2014;	Sangwan,	Tewari,	Singh,	Sharma,	&	Narula,	2013;	Saver,	Hujoel,	
Cunha‐Cruz,	&	Maupome,	2007;	Saxlin,	Suominen‐Taipale,	Knuuttila,	
Alha,	&	Ylostalo,	2009;	Subramanian	et	al.,	2013).	Statin	use	was	not	
found	to	be	associated	with	decreased	tooth	loss	in	adults	with	chronic	
periodontitis	when	analysing	administrative	health	plan	data	(Saver	et	
al.,	2007).	However,	a	5‐year	population‐based	follow‐up	study	com‐
paring	participants	treated	with	statins	with	those	who	did	not	medi‐
cate	with	statins	concluded	that	long‐term	treatment	with	statins	was	
associated	with	reduced	tooth	loss	(Meisel	et	al.,	2014).	Furthermore,	
patients	 on	 statin	 medication	 were	 reported	 to	 exhibit	 significantly	
fewer	signs	of	periodontal	inflammatory	lesions	than	patients	without	
a	statin	regimen	(Lindy	et	al.,	2008).	A	cross‐sectional	study	compared	
the	periodontal	status	of	patients	with	hyperlipidaemia	(with	or	without	
statin	intake)	to	normolipidaemic	individuals	and	found	higher	gingival	
bleeding	and	probing	depths	in	the	hyperlipidaemic	patients	who	were	
not	statin	users	(Sangwan	et	al.,	2013).	In	a	RCT,	periodontal	patients	
with	risk	factors	or	with	established	atherosclerosis	were	assigned	to	
either	high‐	of	low‐dose	statin	intake	(Subramanian	et	al.,	2013).	After	3	
8  |     SANZ et Al.
months,	a	significant	reduction	of	periodontal	inflammation	was	seen	in	
the	high‐dose	compared	to	the	low‐dose	group.	Thus,	within	the	limits	
of	the	above‐reported	studies,	there	is	some	limited	evidence,	suggest‐
ing	that	statins	may	have	a	positive	impact	on	periodontal	health.
Very	few	clinical	studies	have	been	designed	to	evaluate	the	effect	
of	adjunctive	systemic	statin	 intake	 in	conjunction	with	periodontal	
therapy	 (Fajardo,	Rocha,	 Sanchez‐Marin,	&	Espinosa‐Chavez,	 2010;	
Fentoglu	 et	 al.,	 2012;	 Sangwan,	 Tewari,	 Singh,	 Sharma,	 &	 Narula,	
2016).	In	a	randomized	placebo‐controlled	pilot	study	in	38	patients	
with	chronic	periodontitis,	 adjunctive	 statin	 intake	 led	 to	beneficial	
effects	on	radiological	bone	 loss	and	tooth	mobility	after	3	months	
(Fajardo	et	al.,	2010).	Another	3‐month	study	compared	the	treatment	
response	to	nonsurgical	periodontal	therapy	in	107	chronic	periodon‐
titis	patients	 (35	normolipidaemic	as	control,	36	hyperlipidaemic	on	
non‐pharmacological	therapy	and	36	hyperlipidaemic	on	statins)	and	
found	a	greater	improvement	in	gingival	index	in	the	normolipidaemic	
control	and	in	the	statin	groups	(Sangwan	et	al.,	2016).	Based	on	this	
limited	evidence,	 two	recent	systematic	 reviews	with	meta‐analysis	
on	the	effects	of	(local	and	systemic)	statins	on	periodontal	treatment	
concluded	that	systemic	statin	intake	does	not	enhance	the	outcomes	
of	periodontal	therapy	(Bertl	et	al.,	2017;	Muniz	et	al.,	2018).
5  | C ARDIOVA SCUL AR RISKS AND 
COMPLIC ATIONS OF PERIODONTAL 
THER APEUTIC INTERVENTIONS
5.1 | Is there an ischaemic cardiovascular risk for 
patients undergoing periodontal therapy?
Non‐surgical	treatment	of	periodontitis	involving	supra‐	and	subgingi‐
val	instrumentation	of	the	affected	dentition	(under	local	anaesthesia)	
is	often	delivered	 in	 several	 short	 sessions.	Alternatively,	 full‐mouth	
non‐surgical	periodontal	treatment	can	be	performed	within	24	hours.
Delivering	periodontal	treatment	in	a	full‐mouth	fashion	(i.e.	within	
24	hours)	triggers	a	one‐week	acute	systemic	inflammatory	response	
associated	with	transient	impairment	of	endothelial	function	(Orlandi	
et	al.,	2019).	This	distant	effect	is	not	observed	when	periodontal	treat‐
ment	is	delivered	across	several	separate	sessions	(Graziani	et	al.,	2015).	
This	is	achieved	by	limiting	the	number	of	teeth	involved	and	the	time	
devoted	to	completing	the	dental	instrumentation.	These	findings	raise	
the	 question	 of	 whether	 performing	 longer	 sessions	 of	 periodontal	
treatment	could	contribute	to	an	individuals’	inflammatory	burden/risk	
and	 increase	their	short‐term	risk	of	suffering	from	a	vascular	event.	
TA B L E  1  Summary	of	the	evidence	on	the	effect	of	periodontal	therapy	on	surrogate	markers	of	cardiovascular	diseases
Topic Outcome
Number of RCTs 
and SR since last 
consensus References Effect
Overall Level 
of Evidence
Effect	of	Periodontal	Therapy	
on	Lipids
Lipids	(multiple) 6	RCTs Caula,	Lira‐Junior,	Tinoco,	and	Fischer	
(2014);	D'Aiuto	et	al.	(2018);	Deepti,	
Tewari,	Narula,	Singhal,	and	Sharma	
(2017);	Fu,	Li,	Xu,	Gong,	and	Yang	
(2016);	Hada,	Garg,	Ramteke,	and	
Ratre	(2015);	Kapellas	et	al.	(2014)
No Moderate
Effect	of	Periodontal	Therapy	on	
Blood	Pressure
Systolic,	diastolic 3	RCTs D'Aiuto	et	al.	(2018);	Hada	et	al.	(2015);	
Zhou	et	al.	(2017)
Yes Limited
Effect	of	Periodontal	Therapy	on	
Endothelial	Function
Endothelial	
Function	(multi‐
ple	measures)
2	RCTs D'Aiuto	et	al.	(2018);	Saffi	et	al.	(2018) Yes Moderate
1	SR Steffel	et	al.	(2018b)
Effect	of	Periodontal	Therapy	on	
interleukin	(IL)−6
IL−6 3	RCTs Fu	et	al.	(2016);	Kapellas	et	al.	(2014);	
Zhou	et	al.	(2017)
Yes Moderate
Effect	of	Periodontal	Therapy	on	
C‐Reactive	Protein	(CRP)
CRP 5	SR Demmer	et	al.	(2013);	Freitas	et	al.	
(2012);	Ioannidou,	Malekzadeh,	
and	Dongari‐Bagtzoglou	(2006);	
Paraskevas,	Huizinga,	and	Loos	
(2008);	Teeuw	et	al.	(2014)
Yes Moderate
7	RCTs	following	
2014
D'Aiuto	et	al.	(2018);	Deepti	et	al.	
(2017);	Kaushal,	Singh,	Lal,	Das,	and	
Mahdi	(2019);	Caula	et	al.	(2014);	Hada	
et	al.	(2015);	Kapellas	et	al.	(2014);	
Zhou	et	al.	(2017)
Effect	of	Periodontal	Therapy	on	
Pulse	Wave	Velocity	(PWV)
PWV 1	RCT Kapellas	et	al.	(2014) No Limited
Effect	of	Periodontal	Therapy	on	
carotid	intima‐media	thickness	
(cIMT)
Common	cIMT 1	RCT Kapellas	et	al.	(2014) Yes Limited
Abbreviation: RCT,	randomized	clinical	trial;	SR,	systematic	review.
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There	 is	 consistent	 and	 strong	observational	 evidence	 that	 common	
acute	 infections/inflammatory	 responses	are	associated	at	a	popula‐
tion	 level	with	an	 increased	risk	of	vascular	events	within	 the	first	4	
weeks	of	the	infectious/inflammatory	event	(Smeeth	et	al.,	2004).
5.1.1 | At population level
There	is	no	evidence	for	specific	effects	of	periodontal	treatment	pro‐
cedures	on	increasing	ischaemic	cardiovascular	risk.	Two	observational	
studies	reported	no	effect	of	“invasive dental treatment”	in	elevating	is‐
chaemic	cardiovascular	risk	(Chen	et	al.,	2019;	Nordendahl	et	al.,	2018),	
and	one	study	suggested	a	minimal	increased	risk	within	4	weeks	fol‐
lowing	treatment	(Minassian,	D'Aiuto,	Hingorani,	&	Smeeth,	2010).
Chen	et	al.	(2019)	performed	a	case‐crossover	and	self‐controlled	
case	series	using	the	Taiwanese	National	Health	Insurance	Research	
Database,	 including	over	110,000	Myocardial	 Infarction	cases	and	
290,000	 ischaemic	stroke	patients	between	1999	and	2014.	They	
reported	 a	non‐significant	 increase	 in	 the	 incidence	of	myocardial	
infarction	within	the	first	24	weeks	following	“invasive dental treat‐
ment”	 (including	 periodontal	 procedures)	 except	 for	 a	modest	 risk	
of	myocardial	 infarction	during	the	first	week	for	patients	without	
other	comorbidities	(OR	=	1.31,	95%	CI	[1.08;	1.58],	after	3	days).
A	registry‐based	case–control	study	between	2011	and	2013	in‐
cluding	51,880	cases	who	underwent	an	“invasive dental procedure” 
compared	to	246,978	controls	 reported	no	association	with	an	 in‐
creased	incidence	of	myocardial	 infarction	(OR	0.98,	95%	CI	[0.91;	
1.06])	(Nordendahl	et	al.,	2018).
Minassian	et	al.	(2010)	performed	a	self‐controlled	case	series	in‐
cluding	nearly	10	million	participants	included	in	an	insurance	data‐
base	from	2002	and	2006	in	the	United	States.	The	analysis	showed	
that	invasive dental treatment	(largely	comprising	of	tooth	extractions	
and	only	4%	being	non‐surgical	and	surgical	periodontal	procedures)	
is	associated	with	an	 increased	 risk	of	 incident	acute	cardiovascu‐
lar	events	(IR	=	1.5,	95%	CI	[1.09;	2.06])	within	the	first	4	weeks	of	
treatment	recorded.
In	 summary,	 the	 Group	 concluded	 that	 delivering	 periodontal	
treatment	is	safe	with	regard	to	cardiovascular	risk.
5.1.2 | In patients with established CVD
There	is	limited	evidence	on	the	effects	of	“invasive dental treatment” 
on	 the	 incidence	 of	 ischaemic	 events	 in	 patients	with	 established	
CVD	or	after	an	event.
A	small	RCT	on	the	effects	of	the	treatment	of	periodontitis	on	
CVD	 biomarkers	 in	 patients	with	 established	CVD	 (Montenegro	
et	 al.,	 2019)	 showed	 no	 cardiovascular	 adverse	 events	 within	 3	
months	 of	 completion	 of	 scaling	 and	 root	 planing	 (periodontal	
therapy).
In	 the	PAVE	 feasibility	 randomized	 secondary	 prevention	 trial,	
provision	of	 periodontal	 scaling	 and	 root	 planing	 treatment	 in	 pa‐
tients	with	established	CVD	did	not	 increase	the	 incidence	of	car‐
diovascular	 events	 compared	 to	 the	 control	 group	 (community	
treatment)	within	6	months	(Beck	et	al.,	2008).
In	 summary,	 the	 Group	 concluded	 that	 delivering	 periodontal	
treatment	is	safe	with	regard	to	cardiovascular	risk	in	patients	with	
established	CVD.
5.2 | What is the perioperative bleeding risk when 
performing periodontal therapy?
Periodontal	treatment	consists	of	numerous	procedures	with	differ‐
ent	levels	of	bleeding	risk.	This	risk	of	bleeding	is	however	low	in	the	
vast	majority	of	procedures,	and	it	can	be	easily	controlled	with	local	
haemostatic	measures.
Perioperative	 bleeding	 risk	 varies	 according	 to	 the	 extent	
and	 invasiveness	 of	 the	 periodontal	 procedure	 performed.	 The	
majority	 of	 periodontal	 procedures	 may	 be	 grouped	 within	 the	
ESC/AHA/EHRA	 (Steffel	et	al.,	2018a,	2018b).	Low	bleeding	 risk	
group	(frequency	less	than	1%	of	post‐operative	bleeding)	group:	
supragingival	 polishing,	 non‐surgical	 periodontal	 treatment,	 con‐
ventional	 surgical	 periodontal	 treatment	 (conservative,	 resective	
or	regenerative),	tooth	extractions	and	dental	implant	placement.	
Moderate	bleeding	risk	(frequency	between	2	and	5%)	may	be	ob‐
served	 in	major	autogenous	bone	augmentation	procedures	such	
as	 block	 bone	 harvesting,	 sinus	 floor	 elevation	 and	 procedures	
where	 healing	 is	 by	 secondary	 intention,	 such	 as	 free	 gingival	
grafting.	Appendix	S1	summarized	the	main	recommendations	for	
patients	with	antithrombotic	therapy	when	performing	periodon‐
tal	therapy.
5.2.1 | In patients undergoing antiplatelet therapy
Individuals	 undergoing	 single	 acetylsalicylic	 acid	 (ASA)	 therapy	
(aspirin)	 in	 different	 therapeutic	 dosages,	 as	 well	 as	 therapy	 with	
clopidogrel,	ticlopidine	or	ticagrelor,	show	no	statistically	significant	
differences	in	frequency	of	bleeding	events	when	compared	to	con‐
trols,	that	is	subjects	not	undergoing	antiplatelet	therapy	(Doganay,	
Atalay,	Karadag,	Aga,	&	Tugrul,	2018;	Lillis,	Ziakas,	Koskinas,	Tsirlis,	
&	Giannoglou,	2011).
Dual	 antiplatelet	 therapy,	most	 commonly	ASA	 in	 combination	
with	clopidogrel,	may	pose	a	certain	risk	for	post‐operative	bleeding	
complications;	however,	it	appears	that	these	haemorrhagic	events	
may	be	managed	safely	with	local	haemostatic	measures	(Napenas	
et	al.,	2009;	Nathwani	&	Martin,	2016).
Thus,	 current	 evidence	 does	 not	 support	 discontinuation	 of	
antiplatelet	 therapy	before	dental	procedures,	 irrespective	of	 the	
type	of	therapy	employed	(single	or	dual	antiplatelet	therapy)	or	the	
type	 of	 procedure	 performed	 (single,	 multiple	 tooth	 extractions,	
non‐surgical	 and	 surgical	 periodontal	 therapy	 and	 dental	 implant	
procedures).
5.2.2 | In patients undergoing anticoagulant therapy
Vitamin K antagonists
In	patients	taking	oral	anticoagulant	therapy	(vitamin	K	antagonists,	
VKA)	 and	 undergoing	 dental	 extraction,	 minor	 dental	 procedures	
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and	dental	 implant	placement	do	not	 seem	 to	 increase	 the	 risk	of	
bleeding	compared	to	patients	who	discontinue	oral	anticoagulant	
therapy	(Shi,	Xu,	Zhang,	Zhang,	&	Liu,	2017;	Yang,	Shi,	Liu,	Li,	&	Xu,	
2016).	There	may	be	a	higher	post‐operative	bleeding	risk	in	patients	
continuing	 VKA	 and	 undergoing	 either	 minor	 dental	 surgery	 or	
other	higher‐risk	procedures	when	compared	to	non‐VKA	patients	
(Biedermann	 et	 al.,	 2017;	 Shi	 et	 al.,	 2017),	 but	 local	 haemostatic	
agents	appear	to	be	effective	in	controlling	post‐operative	bleeding	
(Madrid	&	Sanz,	2009).
Novel/direct anticoagulants (DOAC/NOAC)
Limited	 trials	 and	 evidence	 are	 available	 on	 the	management	 of	
patients	on	novel	oral	anticoagulant	 (NOAC)	therapy	undergoing	
dental	treatment;	hence,	the	Group	concluded	that	further	stud‐
ies	 regarding	 dental	 procedures	 in	 these	 patients	 are	 strongly	
encouraged.
It	appears	there	is	no	need	for	interruption	of	NOAC	therapy	in	
most	dental	treatments,	due	to	a	low	incidence	of	bleeding	compli‐
cations,	which	can	be	successfully	managed	with	local	haemostatic	
measures	 when	 comparing	 groups	 continuing	 NOAC	 and	 groups	
discontinuing	 NOAC	 therapy	 (Kwak	 et	 al.,	 2019;	 Lababidi	 et	 al.,	
2018;	 Patel	 et	 al.,	 2017;	 Yagyuu	 et	 al.,	 2017)	 and	with	 reported	
timing	of	discontinuation	and	 reinstitution	varying	greatly.	When	
comparing	 NOAC	 patients	 with	 healthy	 individuals,	 there	 seems	
to	be	a	higher	 incidence	of	delayed	bleeding	 (2	days	and	 later)	 in	
those	patients	who	do	not	discontinue	NOAC	therapy	(Miclotte	et	
al.,	2017).
6  | RECOMMENDATIONS
6.1 | Recommendations for oral health professionals 
for use in dental practice/office for people with 
cardiovascular disease (CVD)
•	 Patients	with	periodontitis	should	be	advised	that	there	is	a	higher	
risk	for	cardiovascular	diseases,	such	as	myocardial	infarction	or	
stroke,	 and	 as	 such,	 they	 should	 actively	 manage	 all	 their	 car‐
diovascular	risk	factors	(smoking,	exercise,	excess	weight,	blood	
pressure,	lipid	and	glucose	management,	and	sufficient	periodon‐
tal	therapy	and	periodontal	maintenance).
•	 Patients	 with	 periodontitis	 and	 a	 diagnosis	 of	 CVD	 should	 be	
informed	 that	 they	 may	 be	 at	 higher	 risk	 for	 subsequent	 CVD	
complications,	and	therefore,	they	should	regularly	adhere	to	the	
recommended	 dental	 therapeutic,	 maintenance	 and	 preventive	
regimes.
•	 Patients	collect	a	careful	history	to	assess	for	CVD	risk	factors,	
such	as	diabetes,	obesity,	smoking,	hypertension,	hyperlipidaemia	
and	 hyperglycaemia.	 Patients	 suggest	 that	 the	 patient	 consults	
his/her	physician	if	any	of	these	risk	factors	are	not	appropriately	
controlled.
•	 Oral	health	education	should	be	provided	to	all	patients	with	peri‐
odontitis	and	a	tailored	oral	hygiene	regime,	including	twice‐daily	
brushing,	interdental	cleaning	and,	in	some	cases,	the	use	of	ad‐
junctive	chemical	plaque	control,	may	be	appropriate.
•	 People	presenting	with	a	diagnosis	of	CVD	should	receive	a	thor‐
ough	oral	examination,	which	embeds	a	comprehensive	periodon‐
tal	evaluation,	including	full‐mouth	probing	and	bleeding	scores.
•	 If	no	periodontitis	is	diagnosed	initially,	patients	with	CVD	should	
be	placed	on	a	preventive	care	regime	and	monitored	regularly	(at	
least	once	a	year)	for	changes	in	periodontal	status.
•	 In	people	with	CVD,	if	periodontitis	is	diagnosed,	they	should	be	
managed	as	soon	as	their	cardiovascular	status	permits.
o	 Irrespective	of	the	level	of	CVD	or	specific	medication,	non‐
surgical	periodontal	therapy	should	be	provided,	preferably	in	
several	30‐	to	45‐min	sessions,	in	order	to	minimize	a	spike	of	
acute	systemic	inflammation
o	 Surgical	 periodontal	 and	 implant	 therapy	 when	 indicated	
should	be	provided	in	a	similar	manner	as	in	patients	without	
CVD.
However,	attention	should	be	paid	to:
•	 Hypertension.	 It	 is	 recommended	 to	 measure	 the	 patients’	
blood	pressure	 (after	 appropriate	 relaxation)	before	 the	 sur‐
gical	intervention,	and	in	cases	of	high	blood	pressure	(above	
180/100	according	to	expert	opinion),	the	surgery	should	be	
postponed	until	the	patient's	blood	pressure	is	stabilized.
•	 Medication	 with	 antiplatelet	 and	 anticoagulant	 drugs.	 Since	
periodontal	 and	 implant	 surgical	 procedures	 usually	 impart	
only	 a	 low‐to‐medium	 risk	 of	 bleeding	 in	 general	 terms,	 the	
dentist	should	not	change	a	patient's	medication,	or	in	cases	
of	 doubt,	 he/she	 should	 consult	 the	 physician/cardiologist	
prior	 to	 the	 surgical	 intervention.	Consideration	 should	 also	
be	given	to	the	 local	management	of	bleeding	complications	
that	may	arise.
Current	AHA/ACC/SCAI/ACS/ADA/ESC/ACCP	guidelines	on	periop‐
erative	 management	 of	 antithrombotic	 therapy	 do	 not	 suggest	 dis‐
continuation	of	anti‐platelet	therapy	for	low	bleeding	risk	procedures	
(Douketis	et	al.,	2012;	Grines,	Bonow,	&	Casey,	2007;	Kristensen	et	
al.,	2014).
Various	 approaches	 for	 peri‐operative	 management	 of	 anti‐
coagulant	 therapy	 have	 been	 suggested.	 The	Group	 reviewed	 the	
guidelines	 on	perioperative	management	 of	 vitamin	K	 antagonists	
(VKA)	and	suggested	discontinuation	of	medication	treatment	if	the	
INR	is	4	or	below	for	low	or	medium	bleeding	risk	procedures	(Perry,	
Noakes,	Helliwell,	&	British	Dental,	2007).	However,	if	the	INR	(in‐
ternationalized	normalized	 ratio)	 is	3.5	or	above,	 the	expert	group	
recommends	that	dental	clinicians	seek	advice	and	consult	with	the	
responsible	 medical	 professional.	 Management	 of	 high	 thrombo‐
embolic	risk	cases	should	be	collaborative	in	consultation	with	the	
medical	professional	responsible	for	VKA	therapy	(Kristensen	et	al.,	
2014;	Valgimigli	et	al.,	2018).
After	 reviewing	 novel	 anticoagulant	 (non‐VKA)	 and	 direct	 anti‐
coagulant	(NOAC/DOAC)	therapies	guidelines,	the	Group	concluded	
that	for	 low	bleeding	risk	periodontal	procedures	no	discontinuation	
of	anticoagulants	is	recommended	(Steffel	et	al.,	2018a,	2018b).	These	
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procedures	 could	 be	 performed	 18‐24	 hrs	 after	 the	 last	 intake	 (de‐
pending	on	a	renal	function	assessment	for	the	medication	in	question)	
and	then	restart	6	hrs	following	treatment.	The	expert	group,	however,	
strongly	recommends	that	the	dental	clinician	should	consult	with	the	
responsible	medical	professional.	When	a	medium	bleeding	risk	peri‐
odontal	 procedure	 is	 planned,	 discontinuation	 of	 therapy	 should	 be	
agreed	with	the	medical	professional	responsible	for	and/or	prescrib‐
ing	the	anticoagulant	therapy.
Lastly,	in	cases	of	combined	antiplatelet	and	anticoagulant	thera‐
pies	that	pertain	patients	with	the	highest	thrombotic	and	ischaemic	
risk	(i.e.	chronic	atrial	fibrillation	or	after	an	acute	myocardial	infarc‐
tion	or	 recent	coronary	stenting),	when	periodontal	procedures	 (ei‐
ther	of	low	or	medium	bleeding	risk)	are	required,	any	alterations	in	
medication	 should	be	discussed	 and	agreed	upon	with	 the	 respon‐
sible	medical	 professional	 (Steffel	 et	 al.,	 2018a,	 2018b).	 In	 elective	
periodontal	procedures,	the	operation	should	be	delayed	until	after	
treatment	stabilization	and	appropriate	consultation	with	the	medical	
specialist.
In	cases	of	triple	therapy	(dual	antiplatelet	and	one	anticoagulant)	
or	one	anticoagulant	plus	one	antiplatelet,	such	patients	need	individu‐
alized	management	by	the	responsible	medical	professional	according	
to	their	thrombotic	and	haemorrhagic	risk	(Valgimigli	et	al.,	2018).
It	is	important	to	highlight	that	local	haemostatic	agents	(such	as	
oxidized	cellulose,	absorbable	gelatin	sponges,	sutures,	tranexamic	
acid	mouthwashes,	 compressive	 gauze	 soaked	 in	 tranexamic	 acid)	
should	be	used	and	dental	clinicians	should	consider	the	confound‐
ing	effect	of	local	anaesthetic	with	vasoconstrictors.
•	 Patients	with	 a	 risk	of	 endocarditis	 should	be	premedicated	
with	 antibiotics	 following	 current	 guidelines	 (such	 as	 the	
European	or	the	American	guidelines).
•	 People	with	cardiovascular	disease	who	have	extensive	tooth	
loss	should	be	encouraged	to	pursue	dental	rehabilitation	to	
restore	adequate	mastication	for	proper	nutrition.
People	 without	 a	 diagnosis	 of	 CVD,	 but	 with	 risk	 factors	 for	
CVD	 should	 be	 informed	 about	 their	 CVD	 risk	 and	 referred	 to	
a	 physician	 for	 appropriate	 risk	 assessment,	 diagnostic	 testing	
and	 follow‐up	 care.	 For	 oral	 health	 professionals,	 risk	 assess‐
ment	 may	 be	 performed	 based	 upon	 the	 recommendations	 of	
the	 European Society of Cardiology (Systematic COronary Risk 
Evaluation, SCORE)	 (Sixth	 Joint	 Task	 Force	 of	 the	 European	
Society	 of	 Cardiology	 &	 Other	 Societies	 on	 Cardiovascular	
Disease	 Prevention	 in	 Clinical	 Practice,	 2016).
6.2 | Recommendations for 
physicians and other medical health professions for 
use in cardiology practice
Because	of	 the	potential	negative	 impact	of	periodontitis	on	CVD	
complications,	the	following	recommendations	are	made:
•	 Patients	with	CVD	should	be	advised	that	periodontitis	may	have	
a	negative	impact	on	CVD	and	may	also	increase	the	risk	of	CVD	
events.
•	 Patients	 should	 be	 advised	 that	 effective	 periodontal	 therapy	
may	have	a	positive	impact	upon	CV	health.
•	 For	people	with	CVD,	physicians	should	ask	about	a	prior	diag‐
nosis	of	periodontitis.	If	a	positive	diagnosis	has	been	made,	the	
physician	 should	 seek	 to	 ascertain	 that	 appropriate	periodontal	
care	and	maintenance	are	being	provided.
•	 Patients	with	CVD	should	be	 asked	about	 any	 signs	 and	 symp‐
toms	of	periodontitis,	including	bleeding	gums	during	brushing	or	
eating,	loose	teeth,	spacing	or	spreading/drifting	of	the	teeth,	oral	
malodor	and/or	abscesses	of	the	gums	or	gingival	suppuration.
o	 If	a	positive	history	is	elicited,	then	a	prompt	periodontal	eval‐
uation	should	be	recommended	before	their	scheduled	annual	
check‐up.
o	 In	the	case	of	a	negative	history,	people	with	CVD	should	be	
advised	to	check	for	the	above	symptoms,	and	if	a	positive	sign	
appears,	they	should	visit	their	dentist	at	least	once	per	year.
•	 For	 all	 patients	with	 newly	 diagnosed	 CVD,	 referral	 for	 a	 peri‐
odontal	examination	should	occur	as	part	of	their	ongoing	man‐
agement	of	CVD.	Even	if	no	periodontitis	is	diagnosed	initially,	an	
annual	oral/dental	check‐up	is	recommended.
•	 The	 physician	 should	 liaise	 with	 the	 dental	 surgeon	 over	 peri‐
odontitis	 management	 in	 CVD	 patients	 on	 anticoagulant/anti‐
platelet	therapy	prior	to	the	oral	intervention	and/or	periodontal	
surgery,	to	avoid	excess	bleeding	or	the	risk	of	ischaemic	events.
6.3 | Recommendations for patients at the dental 
surgery/ office who have CVD or are found to be at 
risk of CVD
•	 People	with	CVD	must	 be	 aware	 that	 gum	disease	 is	 a	 chronic	
condition,	which	may	aggravate	their	CVD	and	requires	 lifelong	
attention	and	professional	care.
•	 There	 is	 a	 need	 to	 clean	 the	 teeth	 and	 gums	 very	 carefully	 at	
home.	 Personalized	 advice	 will	 be	 provided	 by	 the	 oral	 health	
professional.
This	may	include	the	following:
•	 Twice‐daily	 brushing	 with	 either	 a	 manual	 or	 electric	
toothbrush;
•	 Cleaning	between	teeth	using	interdental	brushes	where	they	
fit,	and	where	they	do	not	fit,	then	flossing	may	be	useful;
•	 Use	of	 specific	 dentifrices	 and/or	mouth	 rinses	with	proven	
activity	 against	 dental	 plaque,	 if	 advised	 by	 oral	 health	
professionals;
•	 If	left	untreated,	gum	disease	can	lead	to	tooth	loss	and	may	
also	make	CVD	preventive	measures	harder	to	control;
•	 Gum	disease	may	be	present	and	deteriorate	with	no	apparent	
symptoms,	so	the	dentist	should	advise	their	patient	that	even	
without	current	gum	disease,	they	should	still	receive	regular	
dental	check‐ups	as	part	of	managing	their	CVD.
Dentists	should	be	able	to	identify	the	early	signs	of	gum	disease,	but	
patients	should	also	suspect	gum	disease	if	noticing:
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•	 Red	or	swollen	gums;
•	 Bleeding	from	the	gums	or	blood	in	the	sink	after	toothbrushing;
•	 Foul	taste;
•	 Longer	looking	teeth;
•	 Loose	teeth;
•	 Increasing	spaces	between	teeth/	teeth	moving	apart;
•	 Calculus	(tartar)	on	teeth.
Patients	should	inform	their	dentist	about	the	outcome	of	their	visits	
to	the	physician	and	provide	an	update	on	their	CVD	history	and	any	
changes	in	medications.	Patients	should	inform	the	dentist	if	they	are	
on	anticoagulant	therapy.
Patients	 should	 understand	 that	 it	 is	 important	 to	 keep	 their	
mouth	 and	whole	 body	 as	 healthy	 as	 possible	with	 regular	 dental	
and	medical	visits.
6.4 | Recommendations for patients with CVD 
at the physician's practice/office
6.4.1 | Why should I have my gums checked?
If	your	physician	has	told	you	that	you	have	cardiovascular	disease	
(CVD),	you	should	make	an	appointment	with	a	dental	 surgeon	 to	
have	your	mouth	and	gums	checked.
This	 is	because	people	with	CVD	may	have	a	higher	chance	of	
getting	further	complications	when	they	have	gum	disease.	The	ear‐
lier	you	seek	help,	the	better	the	outcome	will	be.
6.4.2 | What should I look for that may tell me I 
have problems with my gums?
You	may	have	gum	disease	if	you	have	ever	noticed:
•	 Red	or	swollen	gums;
•	 Bleeding	from	your	gums	or	blood	in	the	sink	after	you	brush	your	
teeth;
•	 Foul	taste;
•	 Longer	looking	teeth;
•	 Loose	teeth;
•	 Increasing	 spaces	 between	 your	 teeth,	 or	 your	 teeth	 drifting	
apart;
•	 Calculus	(tartar)	on	your	teeth.
If	you	have	noticed	any	of	these	problems,	it	is	important	to	see	a	den‐
tist	as	soon	as	possible.
6.4.3 | Can I have gum disease without these signs 
being present?
Gum	disease	may	also	be	present	and	get	worse	with	no	apparent	
signs	to	you	that	you	have	it,	especially	if	you	smoke,	so	even	if	you	
do	not	think	you	have	gum	disease	now,	you	should	still	have	annual	
check‐ups	of	your	mouth	as	part	of	managing	your	CVD.	Your	dentist	
will	be	able	to	pick	up	early	signs	of	gum	disease.
6.4.4 | What can I do to prevent gum disease?
You	need	 to	 clean	 your	 teeth	 and	 gums	 twice	daily	 at	 home	 for	
a	minimum	of	 2	min.	 Also,	 cleaning	 between	 your	 teeth	 daily	 is	
important	and	your	oral	health	professional	will	show	you	how	to	
do	this.	You	should	visit	a	dental	surgeon	as	soon	as	possible	for	
a	 diagnosis	 and	 advice	 on	what	 you	 need	 to	 do.	 It	 is	 important	
to	keep	your	mouth	as	healthy	as	possible	with	 regular	oral	 and	
dental	care,	according	to	the	recommendations	of	your	oral	health	
professional.
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ANTITHROMBOTIC THER APY: WHEN, HOW 
AND WHY. COMPREHENSIVE APPROACH 
FOR OR AL HE ALTH PROFESSIONAL S
Introduction
The	 use	 of	 antithrombotic	 therapy	 is	 one	 of	 the	 cornerstones	 of	
cardiovascular	 medicine,	 as	 the	 main	 pathophysiological	 event	 is	
thrombus	formation.	The	widespread	use	of	antithrombotic	agents	
is	an	indisputable	fact	and	is	increasing	everyday	with	the	ageing	of	
the	general	population	and	the	unstoppable	growth	of	cardiovascu‐
lar	diseases	 (CVD)	prevalence.	Altogether,	 the	number	of	available	
agents,	 indications	 and	 timing	 of	 these	 therapeutic	 interventions	
is	a	matter	of	constant	discussion	and	controversy.	This	document	
pretends	to	complement	the	current	recommendations	of	the	Joint	
Committee	 of	 the	 European	 Federation	 for	 Periodontology	 (EFP)	
and	 the	World	 Heart	 Federation	 (WHF)	 with	 an	 overview	 of	 the	
rationale	of	the	antiplatelet	and	anticoagulant	therapies	in	the	set‐
ting	of	cardiovascular	disease,	to	increase	awareness	of	the	dos	and	
don´ts	of	these	medications	and	optimize	the	thrombotic	and	bleed‐
ing	of	patients	with	CVD	that	undergo	periodontal	interventions.
Pharmacology of antithrombotic agents
Thrombus	prevention	is	based	on	the	interruption	of	the	haemosta‐
sis,	and	this	can	be	achieved	by	intervening	in	the	primary	haemosta‐
sis	 (namely,	 platelet	 function)	 or	 secondary	haemostasis	 (basically,	
humoral	factors).	Agents	whose	main	target	is	primary	haemostasis	
are	usually	called	antiplatelet	drugs	and	are	widely	used	in	circum‐
stances	 in	 which	 the	 main	 phenomenon	 is	 local	 thrombosis	 (e.g.	
myocardial	infarction,	non‐embolic	strokes,	etc.).	On	the	other	hand,	
drugs	that	alter	secondary	haemostasis	are	generally	referred	to	as	
anticoagulants	and	are	used	 in	conditions	 that	 increase	the	risk	of	
clot	formation	with	subsequent	embolization	(e.g.	atrial	fibrillation,	
deep	vein	thrombosis,	etc.).
Antiplatelet drugs
The	currently	commercialized	antiplatelet	drugs	of	common	use	are:
•	 Acetylsalicylic	acid	(ASA	‐	Adiro®)
•	 AntiP2Y12:	 usually,	 these	medications	 are	 used	 as	 adjuvants	 in	
situations	of	abnormally	high	thrombotic	risk,	such	as	the	months	
after	a	myocardial	infarction	(MI)	or	the	placement	of	a	coronary	
stent.	When	compared	with	ASA,	all	of	these	drugs	have	a	higher	
antithrombotic	power	and,	thus,	a	higher	bleeding	risk.	That	is	why	
it	is	of	no	surprise	that,	when	used	as	adjuvants	therapies	together	
with	ASA,	the	final	risk	of	bleeding	arises	from	a	synergistic	effect	
of	both	drugs	and	is	markedly	elevated	compared	with	single	an‐
tiplatelet	therapy.	As	the	thrombotic	risk	 in	the	aforementioned	
situations	(recent	MI,	recent	coronary	stent	placement)	decreases	
with	time,	the	use	of	these	agents	is	almost	always	limited	for	a	
number	of	months	after	the	event.	These	group	includes:
o	 Clopidogrel	(Plavix®)
o	 Ticagrelor	(Brilique®,	Brilinta®,	Ticalog®)
o	 Prasugrel	(Efient®,	Effient®,	Agrepres®,	Prasugil®,	Prasita®)
The	 last	 two	agents,	namely	 ticagrelor	and	prasugrel,	were	 released	
several	years	after	the	commercialization	of	clopidogrel	due	to	some	
concerns	regarding	the	efficacy	of	the	 latter	 in	selected	populations	
with	resistance	 its	biological	effect.	Both	medications	have	shown	a	
higher	platelet	inhibition	when	compared	to	clopidogrel	with	a	logically	
expected	increase	in	the	bleeding	rates.	No	studies	have	addressed	the	
comparative	risk	of	ticagrelor	against	prasugrel.
There	are	other	 available	 antiplatelet	drugs,	but	 their	use	 is	 re‐
stricted	to	very	specific	and	rarely	situations	that	are	beyond	of	the	
scope	of	this	review	and,	thus,	would	not	be	review.
Anticoagulant drugs
The	span	of	anticoagulant	drugs	is	broader,	as	it	included	both	oral	
and	parenteral	families.	The	oral	anticoagulant	medications	include:
•	 Vitamin	K	antagonists	(VKA):	These	anticoagulants	were	the	first	
oral	agents	in	the	market	and	have	been	available	for	more	than	
20	 years.	 Their	 use	 is	widely	 extended,	 as	 they	 are	 very	 cheap	
agents	and	 the	medical	community	 is	very	comfortable	with	 its	
use.	Another	positive	feature	 is	that	the	dose	can	be	titrated	to	
achieve	higher	or	 lower	 anticoagulant	 effect,	 depending	on	 the	
thrombotic	risk	of	the	patient.	However,	they	have	some	setbacks	
that	are	to	be	considered.	Firstly,	the	dose	is	not	predictable,	so	
the	patient	must	 routinely	undergo	haemostasis	checks	at	 least	
monthly	 to	 adjust	 the	 dosage	 regime.	 In	 addition,	 these	 agents	
are	tightly	bound	to	plasmatic	proteins	and	tend	to	interact	with	
medications	that	displace	them	from	that	union	(e.g.	non‐steroi‐
dal	 anti‐inflammatory	 drugs,	 antibiotics,	 etc.).	 Also,	 their	 effect	
varies	widely	with	vitamin	K	intake	with	the	diet.	All	in	all,	these	
medications	can	be	quite	uncomfortable	for	both	the	patient	and	
the	doctor:	the	patient	has	to	be	disciplined	with	the	diet	and	the	
dosage	regime,	and	should	be	aware	of	all	 the	medications	that	
can	interact.	Physicians,	on	the	other	hand,	have	to	check	these	
patients	up	monthly	to	adjust	the	dose.	The	active	principles	of	
this	group	are:
o	 Warfarin	(Coumadin®,	Farin®,	Aldocumar®)
o	 Acenocumarol	(Sintrom®)
While	 in	North	America	the	use	of	warfarin	 is	much	more	frequent,	
acenocumarol	is	the	preferred	choice	in	Europe.
•	 Direct	 Oral	 Anticoagulants	 (DOACs):	 this	 group	 encompasses	
four	different	drugs	divided	into	direct	thrombin	inhibitors	and	Xa	
factor	inhibitors.	The	benefits	these	medications	have	in	compar‐
ison	with	VKA	is	that	their	dose	is	predictable,	so	no	dose	moni‐
toring	is	necessary.	Also,	their	interactions	are	limited	and	much	
more	 infrequent.	Regarding	outcomes,	 these	drugs	have	 shown	
to	be	at	least	non‐inferior	to	acenocumarol	in	embolic	prevention	
with	a	better	safety	profile	as	measured	by	a	lower	bleeding	risk.	
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This	better	overall	profile	is	the	reason	why	DOACs	are	now	the	
first	line	therapy	with	patients	with	atrial	fibrillation	(AF)	accord‐
ing	 to	 the	 current	 clinical	 practice	 guidelines.	 However,	 not	 all	
the	AF	patients	are	candidates	for	these	medications.	This	group	
includes:
o	 Dabigatran	(Pradaxa®):	available	as	110	mg	or	150	mg	tablets.	
It	is	used	twice	a	day.
o	 Rivaroxaban	(Xarelto®):	available	as	15	mg	or	20	mg	tablets.	It	
is	used	once	daily.
o	 Apixaban	 (Eliquis®):	available	as	2.5	mg	or	5	mg	tablets.	 It	 is	
used	twice	a	day.
o	 Edoxaban	(Lixiana®):	available	as	30	mg	or	60	mg	tablets.	It	is	
used	once	daily.
Other	than	the	above,	sometimes	patients	can	be	on	parenteral	an‐
ticoagulant	therapies	such	as	low	molecular	weight	heparins.	These	
medications	 are	 normally	 used	 during	 short	 periods	 of	 time	while	
bridging	in	between	drugs.
Indications
For single antiplatelet therapy (SAPT)
Every	patient	with	any	form	of	CVD	that	belong	to	the	atheroscle‐
rotic	spectrum	(coronary	artery	disease,	cerebrovascular	disease	or	
peripheral	artery	disease)	should	start	indefinite	treatment	with	an	
antiplatelet	agent.	For	this	indication,	the	most	extended	practice	is	
to	use	ASA,	but	also	clopidogrel	can	be	used.	Ticagrelor	and	prasug‐
rel	are	never	used	in	monotherapy	(Neumann	et	al.,	2008;	Task	Force	
Members	et	al.,	2018).
Although	this	has	been	widely	discussed	during	several	decades,	
the	use	of	ASA	in	primary	prevention	is	currently	not	justified	and	
should	be	avoided.
Other	than	the	above,	there	are	several	conditions	that	also	re‐
quire	the	utilization	of	ASA,	such	as	some	cases	of	antiphospholipid	
syndrome	or	the	presence	of	intracardiac	structural	devices	(mitral	
clip,	atrial	and/or	ventricular	septal	defect	occluders,	bioprosthetic	
valves,	etc.)
For double antiplatelet therapy (DAPT)
•	 Coronary	artery	disease	(CAD):	patients	with	CAD	require	DAPT	
in	 the	 following	 situations	 (Ibanez	 et	 al.,	 2014;	Neumann	 et	 al.,	
2008):
o	 Chronic	 angina	 pectoris:	 after	 the	 implantation	 of	 a	 coro‐
nary	 stent,	 it	 is	 generally	 recommended	 to	 use	 DAPT	 for	
6	months,	after	which	the	patient	can	discontinue	the	sec‐
ond	antiplatelet	drug	and	stay	only	on	ASA.	In	some	cases	of	
high	risk	of	bleeding,	the	duration	can	be	shortened	to	three	
months.	The	only	combination	approved	for	this	scenario	is	
ASA	+	clopidogrel.
o	 Acute	 coronary	 syndrome	 (myocardial	 infarction):	 after	 a	
myocardial	 infarction,	 is	 it	 recommended	 to	use	DAPT	 for	 a	
duration	of	12	months.	However,	in	some	cases,	the	duration	
can	be	shortened	to	only	one	month,	after	which	the	patient	
should	discontinue	the	second	agent	and	remain	on	ASA	 in‐
definitely.	First	month	after	stent	implantation	is	particularly	
critical,	 so	no	patient	should	suspend	DAPT	within	this	 time	
window.	Preferably,	the	patient	should	be	on	ASA	+	ticagrelor/
prasugrel,	but	ASA	+	clopidogrel	is	also	acceptable	if	there	are	
contraindications	for	the	other	agents.
•	 Cerebrovascular	 disease	 (CeVD):	 patients	 with	 CeVD	 require	
DAPT	in	the	following	situations:
o	 Chronic	carotid	disease:	in	symptomatic	patients	with	carotid	
stenosis	 that	 undergo	 carotid	 stenting,	ASA	+	 clopidogrel	 is	
recommended	for	one	month.	After	that,	the	patient	can	dis‐
continue	one	of	the	two	agents	and	remain	indefinitely	on	the	
other	(usually	clopidogrel	is	discontinued).
o	 Acute	ischemic	stroke:	the	use	of	DAPT	for	secondary	preven‐
tion	of	stroke	has	not	shown	consistent	positive	results	in	this	
scenario.	Thus,	it	is	not	routinely	recommended.
•	 Peripheral	artery	disease	(PAD)	(European	Stroke	Organisation	et	
al.,	2012):
o	 Chronic	 lower	 extremity	 artery	 disease:	 in	 symptomatic	 pa‐
tients	that	undergo	lower	limb	percutaneous	revascularization	
(stenting),	ASA	+	clopidogrel	is	recommended	for	one	month.	
After	that,	the	patient	can	discontinue	one	of	the	two	agents	
and	 remain	 indefinitely	 on	 the	 other	 (usually	 clopidogrel	 is	
discontinued).
o	 Acute	ischemic	lower	limb	event:	the	use	of	DAPT	for	second‐
ary	prevention	of	lower	limb	occlusions	has	not	shown	consis‐
tent	positive	results	 in	this	scenario.	Thus,	 it	 is	not	routinely	
recommended.
Chronic Oral Anticoagulation (COA)
There	are	three	main	indications	for	anticoagulation:
•	 Deep	 vein	 thrombosis	 (DVT)	 and	 pulmonary	 embolism	 (PE)	
(Konstantinides	 et	 al.,	 2019):	 both	VKA	 and	DOACs	 are	 autho‐
rized	for	this	indication.	The	duration	of	the	therapy	depends	on	
whether	it	is	assumed	to	be	a	spontaneous	case	(3–6	months)	or	
secondary	 to	a	non‐solvable	condition	 (may	even	be	 indefinite).	
When	using	VKA,	the	optimal	international	normalized	ratio	(INR)	
range	is	2	to	3.
•	 Atrial	arrhythmias	with	high	risk	of	systemic	embolism	(AF,	Atrial	
Flutter):	 the	 indication	 for	 chronic	 anticoagulation	 in	 the	 set‐
ting	of	AF/AFlutter	 is	guided	by	 the	 risk	of	embolism.	Although	
the	method	 for	 the	 risk	 estimation	 varies	worldwide,	 European	
Society	 of	 Cardiology	 (ESC)	 guidelines	 recommend	 the	 use	 of	
CHADSVASc	 scale.	 Generally,	 it	 is	 accepted	 that	 the	 following	
patients	with	a	score	equal	to	2	or	higher	must	use	chronic	oral	
anticoagulant	 therapy.	 For	 this	 indication,	 again,	 both	VKA	 and	
DOAC	can	be	used,	being	the	latter	the	first	line	therapy.	When	
using	VKA,	the	optimal	INR	range	is	2	to	3.
•	 Valve	heart	diseases	with	high	risk	of	systemic	embolism:	this	sit‐
uation	 includes	 significant	mitral	 stenosis	 and	mechanical	 valve	
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prosthesis.	Tissue	valves	are	not	at	a	high	risk	of	systemic	embo‐
lism.	These	situations	are	 the	ones	with	 the	highest	 thrombotic	
risk	in	the	whole	area	of	cardiovascular	medicine.	As	the	“power”	
of	the	anticoagulation	with	DOACs	was	proven	to	be	insufficient	
in	these	patients	and	entailed	an	increased	thrombotic	risk,	VKA	
are	the	only	option.	 In	the	case	of	mitral	mechanical	prosthesis,	
the	optimal	INR	range	is	2.5–3.5,	while	aortic	valve	prosthesis	can	
be	handled	between	2–3.	However,	some	older	prosthetic	models	
are	known	to	be	more	thrombogenic	than	newer	ones	and	could	
require	INR	of	up	to	4.
Combined Therapies: SAPT/DAPT with COA
Usually,	patients	with	 indication	for	chronic	SAPT	with	either	ASA	
or	clopidogrel	and	indication	for	COA	are	encouraged	to	take	COA	
alone.	This	strategy	has	been	assessed	is	several	studies	and	proved	
to	be	safe	from	a	secondary	prevention	point	of	view,	with	a	reduced	
risk	of	bleeding	when	compared	with	concomitant	SAPT	and	COA.
On	the	other	hand,	the	management	of	patients	with	 indication	
for	DAPT	and	COA	 is	normally	 seen	 in	patients	 that	are	undergo‐
ing	coronary	 stent	 implantation	and	have	either	atrial	 arrhythmias	
(more	frequent)	or	mitral	stenosis/mechanical	valves	(less	frequent).	
Depending	on	 the	bleeding	 risk	 of	 the	patients,	 two	different	 ap‐
proaches	can	be	chosen:
•	 Normal	bleeding	risk:	short	period	of	triple	therapy	(1‐3	months	
of	DAPT+COA)	and	a	transition	period	with	SAPT	and	COA	(3‐12	
months).	After	 that,	 it	 is	 recommended	 to	downgrade	 to	simple	
COA	therapy.
•	 High	bleeding	risk:	the	short	period	is	either	reduced	to	1	month	
or	omitted,	leaving	the	patient	on	SAPT+COA	for	a	minimum	of	12	
months.
Treatment withdrawal: safety and rationale
It	is	not	the	purpose	of	this	paper	to	give	recommendations	on	tim‐
ing	and	 indications	of	withdrawal,	but	 rather	explain	 the	changes/
effects	that	the	antithrombotic	withdrawal	entails.
Risks of antiplatelet withdrawal
The	 main	 risk	 of	 SAPT	 withdrawal	 is,	 of	 course,	 the	 increase	 in	
thrombotic	risk	as	explained	by	a	higher	chance	of	MI,	stroke	or	pe‐
ripheral	artery	 thrombosis.	 It	 should	be	noticed	 that	patients	with	
implanted	 stents	 are	 at	 a	much	 greater	 risk	 of	 acute	 events	 after	
SAPT	withdrawal.
Regarding	DAPT,	the	crucial	thing	to	be	understood	is	that	when‐
ever	DAPT	 is	 used,	 an	 abnormally	 high	 thrombotic	 risk	 underlies.	
The	duration	of	DAPT	regimes	depends	on	several	factors,	but	there	
should	be	always	a	preestablished	goal	 (e.g.	6	months,	12	months,	
etc.).	 Transitioning	 from	DAPT	 to	 SAPT	before	 the	preestablished	
goal	 should	 always	 be	 performed	 under	 cardiological	 supervision.	
Specially,	 the	 first	month	after	a	 coronary	 stent	 implantation	 is	of	
vital	importance,	as	discontinuation	of	antiplatelet	therapy	can	eas‐
ily	lead	to	stent	thrombosis,	a	complication	that	could	be	fatal.
After	discontinuing	an	antiplatelet	agent,	the	effect	does	not	wear	
off	immediately:
•	 ASA:	10	days	until	absence	of	effect.
•	 Clopidogrel:	3	days	for	significant	decrease	 in	effect.	5	days	for	
absence	of	effect.
•	 Ticagrelor:	3	days	for	significant	decrease	in	effect.	5	days	for	ab‐
sence	of	effect.
•	 Prasugrel:	5	days	for	significant	decrease	in	effect.	7	days	for	ab‐
sence	of	effect.
Risks of anticoagulation withdrawal
Patients	with	indication	for	COA	that	stop	taking	these	medications	
are	at	an	increased	risk	for	thromboembolic	complications.	The	over‐
all	risk	of	the	thrombotic	complications	highly	depends	on	the	indi‐
cation	for	COA.
In	 patients	with	mitral	 stenosis	 or	mechanical	 heart	 valves,	 the	
discontinuation	of	VKA	leads	to	an	extremely	thrombotic	risk,	spe‐
cially	 for	 patients	with	mechanical	 valves	 in	mitral	 position.	 Thus,	
discontinuation	of	this	therapy	in	such	patients	such	always	be	su‐
pervised	by	cardiovascular	professionals	and	usually	requires	bridg‐
ing	treatment	with	heparin	(Baumgartner	et	al.,	2008).
On	the	counterpart,	patients	without	those	conditions,	can	nor‐
mally	be	off	DOAC/VKA	for	brief	periods	of	time	with	an	assumable	
thromboembolic	risk,	specially	in	patients	with	CHADSVASc	scores	
between	2‐6.	However,	discontinuation	of	VKA	is	not	recommended	
anymore	 for	 procedures	 other	 that	 those	with	 high	 bleeding	 risk.	
After	an	oral	cavity	 intervention	with	significant	bleeding,	DOACs	
can	be	safely	restarted	24	hours	later.
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